Abu Dhabi Health Department Signs MoU with Xlife Sciences to Boost Life-Sciences Sector

By HEOR Staff Writer

September 12, 2023

The Department of Health – Abu Dhabi (DoH) and Swiss firm Xlife Sciences have signed a Memorandum of Understanding (MoU) in a bid to fortify the Emirate’s life-sciences sector. The agreement, which was signed at the Department’s Headquarters, aims to enhance innovation, funding opportunities for life sciences start-ups, and clinical research within the Emirate.

The collaboration is part of DoH’s ongoing efforts to establish Abu Dhabi as a global hub for healthcare and life sciences. It will provide incubation training, mentoring, and commercialisation support to innovators, while also exploring the possibility of a joint funding framework with local ecosystem partners.

Dr. Asma Ibrahim Al Mannaei, Executive Director of Research and Innovation Centre at the DoH, expressed her delight at the collaboration, citing it as a step towards addressing global healthcare challenges and reinforcing the development of Abu Dhabi’s life sciences sector.

Xlife Sciences, represented by CEO Oliver R. Baumann, has established their UAE presence through a partnership with ICEBERG Capital, a company based in Abu Dhabi Global Market (ADGM) and regulated by Financial Services Regulatory Authority (FSRA). ICEBERG Capital will be handling the company’s investment strategy and fund management, further enhancing the life sciences ecosystem in Abu Dhabi.

Abdullah Al Weshah, Managing Director – ICEBERG Capital, commented on the collaboration, expressing excitement at the prospect of supporting the Abu Dhabi Life-Sciences ecosystem and looking forward to establishing a joint funding framework to support start-ups, founders, and projects.

This agreement further cements Abu Dhabi’s position as a global life sciences hub and an incubator for healthcare innovation, while spearheading the transformation of the regional healthcare ecosystem through leveraging sciences and technology. 

Reference url

Recent Posts

Transforming Healthcare with the Gene Therapy Access Model

By HEOR Staff Writer

October 1, 2025

The gene therapy access model is a groundbreaking federal-state collaborative framework designed to improve how transformative treatments are distributed and financed, particularly within Medicaid. This innovative approach answers a key question for patients and policymakers: How can we ensur...
PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic Infrastructure and Care

By HEOR Staff Writer

September 30, 2025

Yesterday PhRMA announced steps to boosting patient access to treatments. The announcement showcases the U.S. biopharmaceutical industry’s initiative to enhance patient access and stimulate economic growth. The announcement outlines a remarkable $500 billion in new U.S. infrastructure spending. I...
NHS Productivity Gains at Risk: Balancing Innovation and Cost Control

By João L. Carapinha

September 25, 2025

The article by Kate Bowie at the BMJ (linked below) highlights NHS productivity gains, reporting a 2.7% year-on-year increase in hospital efficiency for 2024–25 compared with a 3% rise in costs. This improvement is attributed to measures such as shorter hospital stays, reduced ag...